Podcasts about Clinical professor

In this episode of The Pediatric Pharmacist Review, we delve into the 2025 KIDs List—the Pediatric Pharmacy Association's updated guide highlighting key potentially inappropriate medications in pediatric care. This comprehensive list serves as a critical resource for clinicians aiming to enhance medication safety and optimize pharmacotherapy in pediatric populations. Meet the Experts: Dr. Rachel S. Meyers brings a wealth of experience as a Clinical Professor at Rutgers University and a Pediatric Clinical Pharmacist at Cooperman Barnabas Medical Center. Her clinical insights and academic contributions have significantly influenced pediatric pharmacy practice. Dr. David Hoff serves as the Pharmacy Director for Acute Care at Children's Minnesota and holds the position of Section Editor at JPPT. With over 30 years of experience, he has been instrumental in developing and updating the KIDs List, ensuring it reflects the latest evidence and best practices. Key Discussion Points: The evolution and significance of the KIDs List in pediatric pharmacotherapy Strategies for integrating the KIDs List into clinical practice The impact of inappropriate medications on pediatric patient outcomes Collaborative efforts in pediatric medication safety Further Reading: For a comprehensive understanding, access the full 2025 KIDs List here: 2025 KIDs List PDF

A CMO Confidential Interview with Jim Lecinski, Clinical Professor of Marketing at the Kellogg School of Management, author, and former Google VP. Jim discusses why he believes marketers are often overly focused on using AI for productivity improvements versus business growth, the gaps between marketers and the C-Suite highlighted by recent Gartner research, and the difference between "big frontier models" and "shiny objects." Key topics include: why you should avoid "gray market AI", how to manage the 5 AI risks (privacy, accuracy, regulatory, personnel, and reputation), and the false precision that accompanies a focus on intermediate measures like Click Through Rate (CTR). Tune in to hear why he's not a fan of Cannes and how AI helped figure out a wedding invitation calling for "casual to semi-formal beach attire."What should CMOs actually do with AI right now—and how do you avoid chasing shiny objects? Mike Linton sits down with Jim Lecinski, Professor of Marketing at Northwestern's Kellogg School (and author of The AI Marketing Canvas and Winning the Zero Moment of Truth) to unpack the AI application layer: the good, the bad, and the ugly. Jim explains why CEOs-CFOs obsess over growth (not merely efficiency), how to reframe marketing dashboards around business outcomes, and his simple two-by-two for AI use cases (internal productivity vs. external value creation). We cover privacy, legal/regulatory, personnel, and reputational risks—and how to mitigate them—plus a pragmatic roadmap: center on a leading frontier model and layer vetted apps instead of stitching together fragile point solutions. Jim also shares candid takes on Cannes vs. Effies and ends with a challenge: personally build something with AI before year-end.You'll learn:* Growth over cost-cutting: aligning with CEO-CFO priorities and measuring ends, not means* The AI use-case 2×2: internal productivity vs. external, customer-facing value creation* Practical examples (e.g., apparel personalization) that lift CSAT, CLV, and revenue* The 5 risk buckets (privacy, accuracy, regulatory-IP, personnel, reputation) and guardrails* How to choose core models (GPT, Gemini, Claude) and avoid “tool soup”* Why awards that honor outcomes beat awards that celebrate activityGuest: Jim Lecinski — Professor of Marketing, Northwestern Kellogg; former VP Customer Solutions (Americas) at Google; author of The AI Marketing Canvas (2nd ed.) & Winning the Zero Moment of Truth.Host: Mike Linton — former CMO of Best Buy, eBay, Farmers Insurance; CRO of Ancestry.com.Sponsor: Better marketing is built on Quad. See how better gets done at (https://www.quad.com/resources/research-and-tools/return-of-touch-consumer-engagement-has-an-omnichannel-revival?utm_source=cmoconfidential&utm_medium=paid&utm_campaign=001_brand&utm_id=podcastnl1031&utm_content=a-paidemail&utm_vp=)If you're enjoying the show, please like, subscribe, and share with your leadership team. New episodes every Tuesday; companion newsletter on Fridays.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Glowing Older podcast, host Nancy Griffin interviews Dr. Kenneth Pelletier, a clinical professor of medicine and psychiatry at UCSF, about the science of longevity and the role of epigenetics. Dr. Pelletier shares insights into the importance of healthspan over lifespan, and the impact of diet, stress, exercise, and social support on longevity. He also discusses the potential and limitations of biohacking and the growing field of integrative medicine. About Dr. Pelletier Kenneth R. Pelletier, PhD, MD is a Clinical Professor of Medicine, Department of Medicine; Department of Family and Community Medicine; and Department of Psychiatry at the University of California School of Medicine (UCSF) in San Francisco; and a Clinical Professor of Medicine in the Department of Medicine and Department Family and Community Medicine at the University of Arizona School of Medicine in Tucson. At the present time, Dr. Pelletier is a medical and business consultant to the US Department of Health and Human Services, the World Health Organization (WHO), the National Business Group on Health, the Federation of State Medical Boards, the Wild Dolphin Project, and major corporations including Cisco, IBM, American Airlines, Prudential, Dow, Disney, Ford, Mercer, Merck, Pepsico, Ford, Pfizer, Walgreens, NASA, Microsoft ENCARTA, Blue Cross/Blue Shield, United Healthcare, Health Net, the Pasteur Institute of Lille, France, the Alpha Group of Mexico, and the Singapore Ministry of Health. He also serves on the boards of the Rancho la Puerta (Mexico), Nova Institute, Fries Foundation, American Institute of Stress (AIS), American Journal of Health Promotion (AJHP), as a Founding Board Member of the American Board of Integrative Medicine (ABOIM), and as a peer reviewer for the Journal of the American Medical Association (JAMA), the Journal of Occupational and Environmental Medicine (JOEM), Annals of Internal Medicine, Health Affairs, and webMD.  Dr. Pelletier is listed in Who's Who in America and in Who's Who in the World. He has been featured on ABC World News, the Today program, Good Morning America, Dr Oz, the CBS Evening News, 48 Hours, the McNeil-Lehrer Newshour, CNN, FOX News, and CBS Sunday Morning.Dr. Pelletier is the author of 15 major books including the international bestseller Mind as Healer, Mind as Slayer; Holistic Medicine: From Stress to Optimum Health; Longevity: Fulfilling Our Biological Potential; Healthy People in Unhealthy Places; Stress and Fitness at Work; Sound Mind – Sound Body: A New Model for Lifelong Health; The Best Alternative Medicine: What Works? What Does Not?; Stress Free for Good: Ten Scientifically Proven Life Skills for Health and Happiness; New Medicine: How to Integrate Conventional and Alternative Medicine for the Safest and Most Effective Treatment and Change Your Genes – Change Your Life: Creating Optimal Health with the New Science ofEpigenetics.Key TakeawaysEpigenetics is a relatively new science, developed in the last 15 years. Epigenetics are all of the influences that determine our health, wellbeing, and life expectancy after the sperm and ovum unite. Epigenetics plays a crucial role in determining health and life expectancy – 95 % of health, illness, and life expectancy are due to factors other than our genes. The role of diet, stress, physical activity and social support significantly influence genetic expression.There are no longitudinal studies for biohacking. Don'tgo into the periphery and engage in questionable practices. Sort hope from hype.Equal criteria for evaluating the outcomes of alternative and conventional medicine must be applied; both should be held to the same rigorous scientific standards to ensure their acceptability and effectiveness.

In episode 95 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Jasmine Gonzalvo, Clinical Professor of Pharmacy Practice at Purdue University College of Pharmacy and breast cancer survivor. Tune in as Jasmine shares her breast cancer journey and the priorities she has now in survivorship. “Cancer gave me the slap in the face that I needed to be present for the right reasons.”

Today's podcast is titled “The War on Drugs: A 1990s Debate on Prohibition versus Legalization” Recorded in 1995, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas hosts a discussion about the war on drugs with former Cato Institute executive vice president David Boaz, former dean of National College of Criminal Defense Emmett Colvin, FBI special agent Buck Revell, and DEA special agent Phil Jordan. Listen now, and don't forget to subscribe to get updates for the Free To Choose Media Podcast.

In this episode, Maggie Shea sits down with Tom Murdock, Clinical Professor at the University at Buffalo School of Management, to unpack his nontraditional career journey — from corporate consulting to higher education — and how he's helping shape the next generation of entrepreneurs in Western New York.Tom shares how his early passion for economic development led him from Deloitte Consulting in New York City to Buffalo Niagara Partnership, and ultimately back to UB, where he now teaches entrepreneurship and innovation. Through his experience in consulting, business incubation, and education, Tom reveals the real “pain points” of building a meaningful career and a thriving startup ecosystem.Together, Maggie and Tom discuss:The Pain Points of pivoting careers and returning to your hometownLessons from corporate consulting and what they don't teach in business schoolHow UB's incubator programs have helped create 500+ local jobsThe most common mistakes new founders make when chasing funding or market fitThe evolving role of Gen Z in the workforce — and what employers are really looking forWhy successful entrepreneurs don't quit their day jobs — they build smart side hustlesFrom startup growth to student mentorship, this episode highlights how purpose-driven leadership andpractical problem-solving are transforming Buffalo's business landscape.Connect with UB School of Management & Tom Murdock   Website: https://mgt.buffalo.eduLinkedIn: University at Buffalo School of ManagementEmail: murdock2@buffalo.eduConnect with StaffBuffalo & Pain Points PodcastWebsite: https://staffbuffalo.comEpisodes: https://staffbuffalo.com/painpointsLinkedIn | Instagram | Facebook | YouTube: @StaffBuffaloThis episode is all about finding purpose, building resilience, and making an impact right where you are.

Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments.   Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis.  (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis.   (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: ·       Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis,  an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease.  ·       Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems.  ·       Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios:   Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council.  Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø  “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025.   Ø  Treatment and Management of Psoriasis     Ø  Treatment and Management of Psoriatic Arthritis  

Welcome to episode #1006 of Thinking With Mitch Joel (formerly Six Pixels of Separation). Disruption isn't always loud. It's often quiet, slow and deeply human. That's one of the lessons Scott Anthony has spent his career unpacking. As a leading voice on innovation and the managing partner emeritus at Innosight (the consultancy founded by the late Clayton Christensen), Scott has helped global companies navigate the uncertainty that comes with change. He si currently a Clinical Professor of Strategy at Dartmouth's Tuck School of Business. His latest book, Epic Disruptions – 11 Innovations That Shaped Our Modern World, reframes how we think about progress through stories that stretch from gunpowder to generative AI, showing that real innovation rarely arrives overnight (he's also written eight other books). It compounds through persistence, vision and luck. In this conversation, we explore what disruption really looks like inside organizations: the emotional toll of change, why mergers and acquisitions often fail, and how the next generation of intrapreneurs can learn from past innovators rather than repeat their mistakes. We also talk about the future of business education and how AI is rewriting the way we learn, teach, and measure knowledge (and why the classic case study model still has a role to play if it evolves with the times). Scott's perspective is grounded in humility and curiosity, shaped by years of studying leaders who dared to think differently and systems that resisted transformation. Whether you're navigating the next big pivot, building within a legacy organization, or simply trying to understand how the forces of innovation ripple through industries, this conversation offers a rare mix of strategy and soul. It's not about predicting the next big thing, it's about learning to see the patterns in change itself. Enjoy the conversation… Running time: 54:55. Hello from beautiful Montreal. Listen and subscribe over at Apple Podcasts. Listen and subscribe over at Spotify. Please visit and leave comments on the blog - Thinking With Mitch Joel. Feel free to connect to me directly on LinkedIn. Check out ThinkersOne. Here is my conversation with Scott Anthony. Disruptions – 11 Innovations That Shaped Our Modern World. Scott's other books on innovation and strategy. Dartmouth's Tuck School of Business. Follow Scott on LinkedIn. Chapters: (00:00) - Introduction to Disruptive Change. (05:03) - Navigating the Use of AI in Learning. (09:32) - The Language of Collaboration with Technology. (10:32) - Reflections on Clayton Christensen's Influence. (14:19) - The Role of Case Studies in Business Education. (18:21) - Understanding Failure in Business Contexts. (20:44) - The Complexities of Mergers and Acquisitions. (23:02) - The Challenges of Change Management. (25:21) - The Future of Work and Collaboration. (27:16) - Defining Disruption and Collaboration. (28:04) - Epic Disruptions: The Selection Process. (29:24) - The Stories Behind Disruptions. (31:01) - Lessons from Julia Child and Disruption. (34:05) - Understanding Stasis in Business. (38:37) - Why Great Companies Fail. (41:20) - The Role of Incumbents in Innovation. (43:18) - The Emergence of Intrapreneurs. (45:12) - Navigating the Great Unfreezing. (47:36) - The Long Game of Technology Adoption. (49:04) - The Four Questions of Disruption.

Send us a text with your feedback from this session! Session 166 (World Congress - Dublin): Cannabis: Misconceptions and Informing A ProfessionRisk/Reward or Be Informed? The approach is always educational first! Jeff Konin sits down to discuss cannabis in sport and the reality of its usage, including misconceptions. Jeff Konin is a Clinical Professor at Florida International University in Miami, Florida. He serves as the Director of the Doctor of Athletic Training Program and leads the Global Initiative for Cannabinoid Research and Education. As a certified athletic trainer and licensed physical therapist, Dr. Konin served on the clinical staff for the Atlanta Committee for the Olympic Games in 1996 and was the head athletic trainer for the USA wheelchair Paralympic Team that won a world championship gold medal in Vancouver, British Columbia, Canada in 2010. He is a frequent volunteer at the Disney World Marathon races. Jeff advises individual athletes, healthcare professionals, sport organizations, educational institutions, school districts, and companies within the cannabis industry. Nationally, he served as the founding chair of the cannabis task force for the National Athletic Trainers' Association. Jeff is also a member of the American Cannabis Nurse's Association (ACNA), the American Medical Marijuana Physicians Association (AMMPA), the Society of Cannabis Clinicians (SCC), and the Florida CCORC Scientific Program Committee. The World Federation of Athletic Training & Therapy is excited to announce the next International Athletic Training & Therapy Day on February 12th, 2026 (IATTD26)!Use: #IATTD26

In this episode of Talking Sleep, host Dr. Seema Khosla welcomes Dr. Doug Kirsch, Medical Director of Atrium Health Sleep Medicine and Clinical Professor in the Department of Neurology at Wake Forest School of Medicine, and Dr. Fariha Abbasi-Feinberg, president-elect of the AASM and private practice physician with Millennium Physician Group in Fort Myers, Florida, to introduce PLATO—a groundbreaking longitudinal assessment tool for obstructive sleep apnea. The Epworth Sleepiness Scale has been a cornerstone of sleep medicine practice for decades, yet clinicians universally acknowledge its limitations in capturing the full patient experience. Similarly, PAP adherence—while important and part of Medicare's MIPS program—tells only part of the story about treatment success. During his AASM presidency, Dr. Kirsch recognized the need for a more comprehensive metric and convened an expert advisory panel to develop a better solution. The conversation traces PLATO's development journey, which Dr. Rosen described as "Doug's baby with a prolonged gestation." Starting with 44 potential questions and utilizing the ICON methodology, the panel carefully refined the tool to capture domains beyond simple sleepiness—including quality of life, functional impairment, and symptom burden that the Epworth overlooks. Dr. Kirsch and Dr. Abbasi-Feinberg explain the validation process, how the tool discriminates between OSA severity levels, and why certain seemingly similar questions about sleepiness were all retained. The episode addresses practical implementation questions: How is PLATO scored? Why do the first two sections use 5-point scales while the final section uses 10 points? Is it free to use, and how does one access it? Will it integrate into electronic health record systems like Epic? Most importantly, how should clinicians use this tool—will it replace the Epworth for Medicare requirements, or does it serve a different purpose? The discussion also explores how PLATO relates to the recent AHRQ report on OSA treatment outcomes and why the tool focuses on patient-reported symptoms rather than solely cardiovascular endpoints. Dr. Kirsch shares his vision for PLATO's future, including hopes for foundation grants to further study the tool and demonstrate that treating OSA and its associated sleepiness meaningfully improves patient outcomes. Whether you're frustrated with current assessment limitations, interested in value-based care metrics, or seeking better ways to document treatment efficacy beyond adherence data, this episode provides essential insights into a tool that may reshape how we measure success in sleep medicine. Join us for this important discussion about moving beyond PAP adherence and Epworth scores to truly capture what matters to our patients.

Vibhuti Arya, PharmD, MPH, is a Clinical Professor at St. John's University College of Pharmacy and Health Sciences and is an Advisor for Policy, Resilience and Response for the NYC Department of Health and Mental Hygiene.She has worked for the past 15 years to bridge the gap between healthcare, well-being, and equity. A racial dialogue expert, Dr. Arya brings together her experiences in social justice, education, theatre, and mindfulness to create brave spaces for people and systems to intentionally work towards dismantling structural racism.In her role at the Department of Health, she works to integrate pharmacists into public health initiatives, particularly among high-risk, medically underserved areas in NYC, and advises on legislation. Dr. Arya is a Global Lead for Gender Equity and Diversity Workforce Development for the International Pharmaceutical Federation (FIP). She recently gave a TEDx talk on structural racism.We talk through many things including how to continue the work around equity, social justice, and inclusion!

Episode SummaryThe FDA held a rare public hearing to reconsider the safety labels on vaginal estrogen—a pivotal moment for menopause care.In this episode, Dr. James Simon, a leading menopause specialist and clinical researcher, joins Georgie Kovacs to unpack what the hearing revealed, why the current labeling may do more harm than good, and what it means for millions of women experiencing genitourinary syndrome of menopause (GSM), recurrent UTIs, painful sex, and incontinence.Together, they explore how outdated warnings, lack of education, and systemic biases continue to shape women's access to treatment—and what both women and clinicians need to know as change finally takes shape.Discussion PointsWhy is the FDA reconsidering the vaginal estrogen warning label now?What does genitourinary syndrome of menopause (GSM) actually mean—and how common is it?How do current black box warnings limit women's access to safe and effective therapies?What's the real risk of vaginal estrogen and breast cancer—and what does the evidence say?How can updated labeling improve care for UTIs, painful sex, and incontinence?What steps can clinicians take to confidently prescribe vaginal estrogen?What role does the media and misinformation play in perpetuating fear around menopause care?How can women advocate for themselves if their doctor is hesitant to prescribe?What's next for the FDA—and how could this hearing reshape menopause treatment in the U.S.?

0:30 - "The war is over." Trump says he thinks Gaza ceasefire will hold 14:21 - Democrats Praise Israel-Gaza Peace Deal, but Not Trump for Forging It 36:07 - Letitia James and an eye for an eye 55:38 - ANTIFA's Mask Slips: Trump's Roundtable Sends Shadow NGO Network Behind "Riot Inc." Into Panic 01:17:30 - Steven Bucci served America for three decades as an Army Special Forces officer and top Pentagon official and is a visiting fellow in The Heritage Foundation’s Allison Center for Foreign Policy Studies. He joined Dan Proft with reaction to the ceasefire deal in Gaza. 01:35:12 - Paul Vallas is CEO of the McKenzie Foundation and a policy advisor at the Illinois Policy Institute. He ran for mayor of Chicago in 2023 and previously served as CEO of Chicago Public Schools. 01:49:54 - Leland Vittert is NewsNation’s chief Washington anchor and the host of On Balance with Leland Vittert. He joined Dan Proft to talk about his new book: Born Lucky: A Dedicated Father, A Grateful Son, and My Journey with Autism 02:06:51 - William Jacobson is a Clinical Professor of Law and Director of the Securities Law Clinic at Cornell Law School. Founder of LegalInsurrection.com and president of the Legal Insurrection Foundation. See omnystudio.com/listener for privacy information.

In this episode, Ali speaks with Dr. James A. Simon, a leading OB-GYN and "Menopause Whisperer," about his pioneering work in sexual medicine and menopause care. Dr. Simon discusses the challenges and importance of addressing sexual health in gynecology, the evolution of hormone therapy, and the cultural barriers that often prevent open conversations about menopause and women's sexuality.The episode highlights the need for more holistic, individualized care for women, the impact of hormones on health and wellbeing, and the progress still needed in medical education and societal attitudes. Listeners will come away with a deeper understanding of menopause, hormone therapy, and the value of compassionate, open dialogue about women's health and aging.Topics also include how aging has changed over generations, why people got scared of Hormone Replacement Therapy, the prevalence and benefits of testosterone in women, the politics of hysterectomies, how Viagra was happened upon, and how GLP-1s work. FOR MORE ALI MEZEY:ALI - WebsiteALI - LinkTreeFOR MORE JAMES:IntimMedicine Website: https://intimmedicine.com/YouTube: https://www.youtube.com/@intimmedicinespecialists5815/videosFacebook: https://www.facebook.com/IntimMedicineRestore Yourself: A Woman's Guide to Reviving Her Sexual Desire and Passion for LifeBook by Dr. James A. Simon.JAMES BIO:James A. Simon, MD, CCD, MSCP, IF, FACOGDr. James A. Simon is a board-certified Ob/Gyn, and reproductive endocrinologist. He is Clinical Professor of Obstetrics and Gynecology at The George Washington University School of Medicine in Washington, DC. Dr. Simon also holds certifications as an AASECT-Certified Sexuality Counsellor, an ISCD-Certified Clinical Bone Densitometrist, and a Menopause Society-Certified menopause specialist. He has an active private practice, IntimMedicine Specialists® in Washington, DC focused on complicated gynecology, sexual medicine for both men and women, and menopause. Dr. Simon has received numerous awards including: “Top Washington Physicians,” “America's Top Obstetricians and Gynecologists,” “Super Doctors of Washington DC-Baltimore-Northern Virginia,” and “The Best Doctors in America.” He is the only physician to serve as President of both The Menopause Society and the International Society for the Study of Women's Sexual Health. Nicknamed “The Menopause Whisperer,” by Washingtonian Magazine, Dr. Simon is an established researcher and author--completing more than 450 research trials, and more than 800 published articles, abstracts, chapters, and the paperback book: Restore Yourself: A Woman's Guide to Reviving Her Sexual Desire and Passion for Life. Dr. Simon loves riding the best rollercoasters in the world, collecting fountain pens and wristwatches, and freshwater fishing. He is a five-time Master Angler of Canada.hiker, dog trainer, and lover of nature.OTHER RESOURCES, LINKS AND INSPIRATIONS: ASECT (American Association of Sexuality Educators, Counselors and Therapists)A professional organization for sexuality educators, counselors, and therapists.ISCD (International Society for Clinical Densitometry)Organization focused on bone density and skeletal health.Menopause SocietyFormerly known as the North American Menopause Society (NAMS), dedicated to promoting the health and quality of life of women through an understanding of menopause.International Society for the Study of Women's Sexual Health (ISSWSH)Multidisciplinary, academic, and scientific organization dedicated to women's sexual health.Washingtonian Magazine ArticleRegional magazine that dubbed Dr. Simon "The Menopause Whisperer."Sexual Health AllianceOrganization and conference for sexual health professionals.Women's Health Initiative Hormone StudiesLandmark studies on hormone therapy in women.Menopause MeetingsAnnual conferences for menopause specialists.PremarinEstrogen medication derived from pregnant mares' urine, historically used in hormone therapy.Viagra (Sildenafil)Medication for erectile dysfunction, originally developed for high blood pressure.GLP-1 Receptor AgonistsClass of injectable medications for diabetes and weight loss (e.g., Ozempic, Wegovy).Dr. Dympna RenshawSouth African psychiatrist and pioneer in sexual medicine, especially in the context of trauma and dysfunction.Halle Berry, Kate WinsletCelebrities mentioned for their advocacy and openness about menopause.Contraception Marches (late 1960s)Historical reference to activism for access to contraception.[From time to time, a word or phrase goes wonky. Please forgive my wandering wifi.]

Today's podcast is titled “Liberal, Objectivist, Conservative: Divergent Voices in America” Recorded in 1998, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas hosts a discussion about three distinct ideological frameworks with CPAE professional speaker and author Phil Wexler, philosopher and author Leonard Peikoff, and Chair and CEO of the Eagle Forum Phyllis Schlafly. Listen now, and don't forget to subscribe to get updates for the Free To Choose Media Podcast.

Menopause is a significant phase in a woman's life, yet it is often surrounded by misconceptions and misinformation. Join our conversation with Dr. Karen Adams, Clinical Professor of Obstetrics and Gynecology at Stanford University, as she unpacks the complexities of menopause and hormone therapy. Discover the impact of the Women's Health Initiative and how it shaped the conversation around hormone use, leading to a dramatic decline in its adoption. Dr. Adams will also address common myths, explore effective non-hormonal treatment options, and share insights on managing symptoms through lifestyle changes. This discussion will provide you with practical tools and a deeper understanding of menopause, helping to demystify this important life transition. Read Transcript: https://mcdn.podbean.com/mf/web/tv5a6jejhjre5pru/medcast_episode111.pdf CME Information: https://stanford.cloud-cme.com/medcastepisode111 Claim CE and MOC: https://stanford.cloud-cme.com/Form.aspx?FormID=3582  

Ever wonder if it's possible to feel joy—even when life is at its hardest as a mother? In this life-changing session, Dr. Tanmeet Sethi opens up about facing unimaginable challenges as a mom and what she has learned about feeling joy alongside the pain. Dr. Sethi will also teach science-backed, practical ways we as mothers can move thorugh hard times bette with joy--yes, joy--along for the ride. This session will help you discover why joy is an act of resistance, how to find hope in the hardest moments, and practical steps to reclaim your aliveness—no matter what you're facing. ⁠Get the Basic Pass⁠ to watch and/or read each speaker session for free through Sunday, October 12th. Upgrade to the All-Access Pass for ad-free listening on a private podcast feed, + lifetime access to all content visual, audio, and written.  FREEBIE for all: Your Integrative Physician newsletter on Substack BONUS raffled off to All-Access Pass Holders: Joy is My Justice book Tanmeet Sethi, MD is an Integrative and Psychedelic Medicine Physician, activist, author, and TEDx speaker who has dedicated her career to care for the most marginalized patients as well as global communities traumatized by manmade and natural disasters as senior faculty for The Center for Mind Body Medicine. Her first book, Joy Is My Justice, (Hachette, 2023) is a radical call to claim Joy as our birthright and the deepest liberation we can know. She is a Clinical Professor at the University of Washington and a primary clinical investigator there on the sacred plant medicine, psilocybin.  FOLLOW ON IG WEBSITE Learn more about your ad choices. Visit megaphone.fm/adchoices

Today's podcast is titled “Ayn Rand and Objectivism: Is Atlas Shrugging?” Recorded in 1998, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas speaks with philosopher and author Leonard Peikoff about Objectivism, Ayn Rand, and her novel, Atlas Shrugged. Listen now, and don't forget to subscribe to get updates each week for the Free To Choose Media Podcast.

12 - After calls for politicians to tone down their rhetoric, Democrat officials are using every Nazi or Nazi-adjacent word in the book to describe Republicans. Dom shows the hypocrisy to start the show. 1210 - Side - a change for the worse 1220 - Your calls. Whose birthday is it today? The Boss's! What is your least favorite thing about him? 1230 - Have the Tampa Bay Buccaneers figured out how to stop the Tush Push? 1235 - Senior Medical Analyst for Fox News, is also a Clinical Professor of Medicine and a practicing internist at NYU Langone Medical Center, Dr. Marc Siegel, joins us today. After hearing what Trump and RFK's messaging was compared to Dr. Oz's on Tylenol use during pregnancy, what is Dr. Siegel's expert opinion on it? Is there a direct link between poor mental health and the overconsumption of spectacularized media like our social media? Is Dr. Siegel doing radio? 1240 - Your calls. 1250 - Your calls to round out hour one. What kind of influencers can match Scott Presler's influence in-person?

12 - After calls for politicians to tone down their rhetoric, Democrat officials are using every Nazi or Nazi-adjacent word in the book to describe Republicans. Dom highlights the hypocrisy at the start of the show. 1210 - Side - a change for the worse 1220 - Your calls. Whose birthday is it today? The Boss's! What is your least favorite thing about him? 1230 - Have the Tampa Bay Buccaneers figured out how to stop the Tush Push? 1235 - Senior Medical Analyst for Fox News, is also a Clinical Professor of Medicine and a practicing internist at NYU Langone Medical Center, Dr. Marc Siegel, joins us today. After hearing what Trump and RFK's messaging was compared to Dr. Oz's on Tylenol use during pregnancy, what is Dr. Siegel's expert opinion on it? Is there a direct link between poor mental health and the overconsumption of spectacularized media like our social media? Is Dr. Siegel doing radio? 1240 - Your calls. 1250 - Your calls to round out hour one. What kind of influencers can match Scott Presler's influence in person? 1 - Continuing with the Nazi rhetoric used towards ICE. Do Democrats not understand that their verbiage is the reason they have to mask up to do their job? No, because that's the message they're using for the 2028 election. 105 - Your calls. 120 - The ICE facility shooter in Dallas was clearly not targeting detainees after his search history has been made public. Your calls. 135 - How many California schools have forfeited their girls' volleyball matches due to transgender player AB Hernandez roaming on the other sideline? 140 - Your calls. 150 - Breaking News: Mikie Sherrill was not allowed to walk at her USNA graduation. Why? She won't say. 2 - We're filibustering until Matt Rooney joins us! 215 - Dom's Money Melody! 220 - Release the records! Matt Rooney, Save Jersey's Founder & Blogger-in-Chief, joins us as the news breaks that Mikie Sherrill did not walk at her college graduation due to a cheating scandal. How big of a blow will this be to her campaign if she cannot tell us why that happened? Are these recent polls on the governor's race spell disaster for the Sherrill campaign? When is the last time the police union endorsed a Republican candidate? There will be 3 bloviators from 1210 at Jack Ciattarelli's event down the shore? 240 - Some updates on the Dallas shooter. Does The Inquirer do breaking news? Linda Kerns joins us late with some breaking news on Pennsylvania voter registrations. Why does the Trump administration want to see their voter rolls? 250 - The Lightning Round!

1 - Marc Siegel, M.D., the Senior Medical Analyst for Fox News, is also a Clinical Professor of Medicine and a practicing internist at NYU Langone Medical Center, joins The Dom Giordano Program today. What is the big news with MMR vaccines coming down today and why does Marc think it's important? Could we wait up to a month before giving newborns their vaccines? Should pharmaceutical ads be allowed to play on television, as RFK Jr. looks to implement rules to tell viewers all possible side-effects of their products? Is looking at giving pain relievers to pregnant women a good thing? 115 - What should be done about the pharmaceutical advertisements? 130 - We discuss the four Republicans who didn't vote on the Charlie Kirk bill. Why would they do that? 140 - Your calls. 145 - AOC chooses to disparage Charlie Kirk as she reasons why this bill should not be passed and why she didn't vote on it. Was he “ignorant and uneducated”? 155 - President Trump will meet with Chinese President Xi twice, once stateside and another in China. What will happen with TikTok?

12 - Dom kicks off Friday with a vote in the house on whether or not to honor Charlie Kirk as a patriot? Dom runs through the surprises and stalwarts in the “Yeas”, “nos”, “present” , and “did not vote” categories? 1210 - Stephen Colbert speaks out on his show on behalf of Jimmy Kimmel getting canceled. 1215 - Side - all-time spinoff 1230 - Pastor Kenneth Whalum Jr. joins us today from Memphis, Tennessee. How did the pastor end up with a law degree with some local ties? Why, as a Democrat, has he been calling for the National Guard to take control of crime downtown? How does the pastor view the city's District Attorney? Is his congregation supportive of his views? What does the pastor implore his opposition to read? How long would the National Guard be in Memphis? 1240 - Your calls. 1250 - Touching on what is to come. 1 - Marc Siegel, M.D., the Senior Medical Analyst for Fox News, is also a Clinical Professor of Medicine and a practicing internist at NYU Langone Medical Center, joins The Dom Giordano Program today. What is the big news with MMR vaccines coming down today and why does Marc think it's important? Could we wait up to a month before giving newborns their vaccines? Should pharmaceutical ads be allowed to play on television, as RFK Jr. looks to implement rules to tell viewers all possible side-effects of their products? Is looking at giving pain relievers to pregnant women a good thing? 115 - What should be done about the pharmaceutical advertisements? 130 - We discuss the four Republicans who didn't vote on the Charlie Kirk bill. Why would they do that? 140 - Your calls. 145 - AOC chooses to disparage Charlie Kirk as she reasons why this bill should not be passed and why she didn't vote on it. Was he “ignorant and uneducated”? 155 - President Trump will meet with Chinese President Xi twice, once stateside and another in China. What will happen with TikTok? 2 - Congressman Jeff Van Drew joins us after a wild two week news cycle. What does Jeff think of those voting against the Charlie Kirk resolution? Why would anyone vote “present”? Jeff discusses how Democrats who never spoke on behalf of the Epstein victims in the years since that story broke, are suddenly bringing that up at Kash Patel's hearing on the FBI. Why is Jeff pushing for meaningful legislation and leadership again? What is Jeff passionate about this week? Are we doing pull-ups? 215 - Dom's Money Melody! 225 - UPenn grad, incoming MIT student dedicated to combatting anti-semitism Eyal Yakoby joins the program here today. What made Charlie so special that he got thousands of students to turn out everywhere he went? How did different opinions become so hostile and shocking on college campuses that it would eventually resort to violence? Eyal leaves us with a powerful note. 250 - The Lightning Round!

Today's podcast is titled “Culture in America: The Three Biggest Challenges Facing Western Civilization, Part Two.” Recorded in 2007, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas and former CIA official, author, and recipient of the U.S. National Intelligence Distinguished Service Medal, Herb Meyer continue their discussion about the three biggest challenges facing Western civilization. Listen now, and don't forget to subscribe to get updates each week for the Free To Choose Media Podcast.

New York Times & Wall Street Journal Best-Selling AuthorMy Guest, New York Times best-selling author Dr. Norman Rosenthal is the world renowned psychiatrist, researcher, and best-selling author, who first described seasonal affective disorder (SAD) and pioneered the use of light therapy as a treatment during his twenty years at the National Institute of Mental Health. A prolific researcher and author, he has authored or co-authored over three hundred scholarly articles and ten popular books. These include Winter Blues, Poetry Rx, the New York Times bestseller Transcendence and the national bestsellers, The Gift of Adversity and Super Mind.He is known for his innovative research and inspirational writings. He is currently Clinical Professor of Psychiatry at Georgetown University School of Medicine and is listed as one of the Best Doctors in America. Dr. Rosenthal has practiced psychiatry for over three decades, treating people with all manner of psychiatric and emotional health issues. He is also a motivational speaker and a personal and professional coach, working with people from all walks of life including CEOs, top athletes, and performing artists.His work & books have received international praise & interviews from CNN News Anchor Candy Crowley, film maker/television director David Lynch, Hip Hop Icon Russell Simmons, comic/actor Russell Brand, Dr. Mehmet Oz, musicians Moby, Paul McCartney, Ringo Starr & many othersRosenthal was born and raised in South Africa and did his medical training at the University of Witwatersrand, where he graduated with high honors. He immigrated to the US and did his psychiatric residency at Columbia in NYC before going to the National Institute of Health in Bethesda, Maryland, where he began his research career in earnest. His first major research contribution was to describe and name Seasonal Affective Disorder (SAD) and to develop light therapy as a treatment for this novel condition. SAD – and its milder variant, the Winter Blues – are now known to affect millions of people worldwide, many of whom have benefited from the light therapy that Dr. Rosenthal pioneered.© 2025 Building Abundant Success!!2025 All Rights ReservedJoin Me on ~ iHeart Radio @ https://tinyurl.com/iHeartBASSpot Me on Spotify: https://tinyurl.com/yxuy23baAmazon Music ~ https://tinyurl.com/AmzBASAudacy:  https://tinyurl.com/BASAud

Imagine you're a marketing professor who saw the AI revolution coming years before ChatGPT hit the scene, wrote the definitive book on AI marketing in 2021, and now find yourself at the epicentre of one of the most dramatic transformations in history.This is the very position this week's guest, Jim Lecinski, finds himself in. Jim is a Clinical Professor of Marketing at Northwestern University's prestigious Kellogg School of Management, where he teaches AI in Marketing and has won Professor of the Year. Adding to Jim's canny foresight is his prior, 13-year career as a VP at Google. As a result, Jim brings both the practitioner's real-world experience and the academic's analytical rigour to one of the most important questions facing leaders and marketers today: how do you harness AI not just for efficiency gains, but for genuine competitive advantage and growth?In our conversation, you'll also hear about:Jim's 2x2 framework for thinking strategically about AI applications in marketing Use-case examples from brands such as Coca-Cola, Starbucks, and IKEA where AI is used to revolutionise everything from creative development to customer serviceWhy businesses need to prepare for the shift from search engine optimisation (SEO) to "generative engine optimisation" (GEO), and what that means practicallyThe emerging world of AI agents and how this will fundamentally change how we all shop, andJim's essential learning resources for those who want to stay ahead of the curve.We loved the way Jim shares his own wisdom and insights as well as sharing many examples of what market leaders are actually doing with AI.We know you'll enjoy this conversation with the whip-smart professor who saw the AI future ahead of the crowd. Useful LinksJim Lecinski on LinkedInAI Marketing Association Marketing AI Institute Andrew Ng's AI for Everyone course on Coursera Hosted on Acast. See acast.com/privacy for more information.

What happens when you stay open to new people, new ideas, and unexpected doors? For Professor Michael Vallely—Cardiothoracic Surgeon, Clinical Professor, Med-Tech Investor, and Entrepreneur—openness has led to a career that spans continents, innovations, and industries. With more than two decades and thousands of complex cardiac cases in Australia and the U.S., Michael has pioneered “first-in-man” procedures and helped shape the future of heart surgery. He's held senior roles at The Ohio State University and Mount Sinai Hospitals, is currently Professor at Macquarie University, and practices cardiothoracic surgery in the public and private sector across Sydney. As founder and Chief Medical Officer of Sydney Heart Valve, Michael is leading the development of next-generation transcatheter heart valve technologies—delivering minimally invasive options for patients with structural heart disease. He is also a founding partner and Chair of the Medical Advisory Panel at Cordis Asset Management, a boutique fund manager investing in innovative medical technology companies that are transforming the treatment of chronic disease. In this episode, Michael shares his journey to building a dynamic portfolio career. Together, we explore: How openness to people and opportunities transformed his journey How serendipity and “the company we keep” matter more than any single destination The pivotal moments, mentors, and mindset shifts that shaped his career On resilience: truly knowing your strength comes when tested Mentor advice and book recommendations that shaped his leadership Whether you're a clinician, innovator, or simply curious about the intersection of medicine, technology, and personal growth, this conversation is for you. After each episode, our Mentors give an additional hour of their time to mentor a listener. We do this because we believe real growth happens through connection, learning, and paying it forward. Share this episode on your socials with #medtechmentorpodcast and tell us what stuck with you—whether it was a story, an idea, a question, or just a moment you enjoyed. You'll go in the running for an exclusive one-on-one mentoring conversation with Michael Vallely. Don't miss your chance to connect—subscribe and share today! References & Further Reading: Michael Vallely's LinkedIn Sydney Heart Valve Cordis Asset Management Principles by Ray Dalio

Episode 061 | Arisa E. Ortiz, MD is the Founder/Creator of Your Pre-Visit, Director of Laser and Cosmetic Dermatology, and a Clinical Professor of Dermatology at the University of California, San Diego. She received training in Mohs Micrographic Surgery at UC San Diego and also completed the prestigious cosmetic and laser fellowship at Massachusetts General Hospital, Harvard Medical School, and Wellman Center for Photomedicine. Dr. Ortiz completed her dermatology residency training at UC Irvine and Beckman Laser Institute. She has authored over sixty publications and several book chapters. Dr. Ortiz also coedited a textbook on surgical reconstruction. She has presented at international and national conferences and is frequently an invited speaker at the American Academy of Dermatology (AAD), American Society for Dermatologic Surgery (ASDS), and the American Society for Laser Medicine and Surgery (ASLMS). She is on the editorial board of the Journal of Lasers in Surgery and Medicine and has won several awards including the ASLMS Dr. Horace Furumoto Young Investigator Award and ASLMS Best of Session Award for Cutaneous Applications, ASDS President's Outstanding Service Award, Castle Connolly Top Doctors Award, Exceptional Women in Medicine, and Newsweek America's Best Dermatologists. She has also been featured on The Doctors & Dr. Pimple Popper. Dr. Ortiz has served as the President of the San Diego Dermatologic Surgery Society and President of ASLMS. Her research interests are in laser treatment of non-melanoma skin cancer.This episode was recorded on March 24th, 2025.Connect with and learn from Dr. Rubin and SEENArisa Ortiz, MD (arisaortiz@gmail.com)Dr. Ortiz on IGYour Pre-Visit (Use code DERM60 for an extended free trial!)YPV on IGMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.Above & Beyond DermatologyNutrafol -- special pricing and physician exclusive productsNeoGenesis -- my favorite source of stem cell released molecules for skin/hairSilagen.biz -- physician dispensed scar refinement products delivered to your door (use practice code 1206240832P)NewsletterLinkedInFacebookDr. Lewellis on InstagramAbove & Beyond Dermatology on InstagramYouTubeTikTokTwitter/XChange Your Mind, Change Your LifeSoMeDocs (Doctors on Social Media)Pippa!

Heart disease is the number one cause of death in the United States. Leading cardiologist, Dr. Joel Kahn, talks about how to reduce your risk of heart disease by changing your lifestyle. Eating a majority plant-based diet, stopping smoking, and getting enough sleep are key factors in heart health.  Best Supplements for Optimal Heart Health Vitamin D CoQ10 Magnesium Melatonin Berberine About Dr. Joel Kahn ⁠Dr. Joel Kahn⁠ is a practicing cardiologist in Detroit, Michigan, and a Clinical Professor of Medicine at Wayne State University School of Medicine. He graduated Summa Cum Laude from the University of Michigan Medical School. Known as "America's Healthy Heart Doc", Dr. Kahn has triple board certifications in Internal Medicine, Cardiovascular Medicine, and Interventional Cardiology. He was the first physician in the world to certify in Metabolic Cardiology with A4M/MMI and the University of South Florida. He founded the Kahn Center for Cardiac Longevity in Bingham Farms, MI. In This Episode How serious heart disease is [4:00] How to prevent heart disease [5:30] How we should be eating for heart disease prevention [8:30] Why we should reduce our consumption of animal products [10:30] What nutrient deficiencies someone on a plant-based diet might have [19:30] The top nutrients for optimal heart health [21:30] Sources of cholesterol on a plant-based diet [29:00] What percentage of your diet should be plant-based [30:00] What blood tests indicate heart disease [36:00] Links & Resources Use code OMEGA3S to get 10% off ⁠OMEGA3S Use code COQ10 to get 10% off ⁠⁠⁠⁠COQ10 ⁠Use CODE BERGAMOT to get 10% off ⁠⁠Citrus Bergamot ⁠Find Dr. Joel Kahn Online⁠ ⁠Find the Kahn Center for Cardiac Longevity Online⁠ Follow Dr. Joel Kahn on ⁠Instagram⁠ | ⁠Facebook⁠ | ⁠Twitter⁠ | ⁠YouTube⁠ ⁠Find Your Longevity Blueprint Online⁠ Follow Your Longevity Blueprint on ⁠Instagram⁠ | ⁠Facebook⁠ | ⁠Twitter⁠ | ⁠YouTube⁠ | ⁠LinkedIn⁠ ⁠Get your copy of the Your Longevity Blueprint book and claim your bonuses here⁠ ⁠Find Dr. Stephanie Gray and Your Longevity Blueprint online⁠   Follow Dr. Stephanie Gray on ⁠Facebook⁠ | ⁠Instagram⁠ | ⁠Youtube⁠ | ⁠Twitter⁠ | ⁠LinkedIn⁠ ⁠Integrative Health and Hormone Clinic⁠ Podcast production by Team Podcast⁠⁠⁠⁠  Related Episodes ⁠Episode 69: Pluck Seasoning With James Barry⁠ ⁠Episode 67: A Different Kind Of Healing With Dr. Shiroko Sokitch⁠ ⁠Episode 11: Intermittent Fasting Truths With Cynthia Thurlow

Dr. Marc Siegel, Clinical Professor of Medicine & Fox News Contributor, joins the program on this Tuesday installment of Sid & Friends in the Morning. Learn more about your ad choices. Visit megaphone.fm/adchoices

Across the country, bar associations are increasingly at the center of legal and political controversy. Recent disciplinary proceedings—such as efforts by the DC Bar to disbar Acting OIRA Administrator Jeffrey Clark, ethics complaints against Montana Attorney General Austin Knudsen and Ninth Circuit Judge Lawrence VanDyke—have raised urgent questions about the line between professional regulation and ideological weaponization of legal licensing.Are these proceedings neutral applications of ethical standards, or do they reflect growing pressure to use professional discipline as a political weapon? What procedural and constitutional safeguards exist to protect the federal government from state licensing authorities and to protect lawyers against viewpoint discrimination? Are these tools sufficient? How should courts, bar associations, and the legal academy understand their roles in preserving both public trust and ideological diversity within the profession? Featuring: James M. Burnham, Founder and Managing Partner, King Street Legal, PLLCMichael Francisco, Partner, First & Fourteenth PLLCGene P. Hamilton, President & Co-Founder, America First Legal FoundationProf. Derek T. Muller, Professor of Law, Notre Dame Law School(Moderator) Prof. Denise M. Harle, Clinical Professor and Director of the First Amendment Clinic, Florida State University College of Law

Welcome to another episode of the Sustainable Clinical Medicine Podcast! This week, Dr. Sarah Smith sits down with Dr. Diane Sliwka, Chief Physician Experience Officer at UCSF, to explore what it really takes to create a sustainable and fulfilling career in medicine. Dr. Sliwka shares her personal journey through hospital medicine, the challenges of burnout, and how systemic change and leadership can make a real difference for clinicians. Together, they discuss practical strategies for improving work-life balance, the power of advocacy, and the importance of open communication in healthcare organizations. Whether you're a physician, healthcare leader, or anyone interested in the future of clinical practice, this episode is packed with insights and inspiration to help you thrive in your career and support a healthier medical community. Here are 3 key takeaways from this episode: Systemic Change Is Essential for Combating Burnout: Dr. Sliwka's experience highlights that physician burnout is often rooted in systemic issues—such as long hours, inflexible schedules, and excessive documentation. Addressing these challenges requires organizational change, not just individual resilience. Leadership and Advocacy Make a Difference: Taking on leadership roles and advocating for change within the system can lead to meaningful improvements. Dr. Sliwka's journey shows that when clinicians step into leadership and use data to drive decisions, they can influence policies that support well-being, such as improved scheduling, documentation support, and wellness initiatives. Continuous Improvement and Open Communication Are Key: Sustainable clinical practice depends on ongoing feedback, open communication between frontline staff and leadership, and a willingness to adapt. Initiatives like anonymous surveys, regular check-ins, and a culture that values listening to clinicians' needs are crucial for creating a healthier, more supportive work environment. Meet Dr. Diane Sliwka: Diane Sliwka, MD is a Hospitalist and Clinical Professor of Medicine in the Division of Hospital Medicine at the University of California San Francisco Medical Center. In her role as Chief Physician Experience Officer at UCSF Health, she has led provider experience efforts organizationally since 2014. Diane co-designed and facilitated UCSF's well-being centered leadership development program for physicians. She also leads UCSF Health's Center for Enhancement of Communication in Healthcare which provides relationship centered communication skills training for providers. She hosts “The Expansive Life Project” on Instagram, providing personal well-being resources and tips focused on mid-career working professionals. You can find Dr. Sliwka on: Instagram: https://www.instagram.com/theexpansivelifeproject/ Linked In: linkedin.com/in/diane-sliwka-md-59122413b UCSF Web Bio: https://hospitalmedicine.ucsf.edu/people/diane-sliwka -------------- Would you like to view a transcript of this episode? Click Here **** Charting Champions is a premiere, lifetime access Physician only program that is helping Physicians get home with today's work done. All the proven tools, support and community you need to create time for your life outside of medicine. Learn more at https://www.chartingcoach.ca **** Enjoying this podcast? Please share it with someone who would benefit. Also, don't forget to hit “follow” so you get all the new episodes as soon as they are released. **** Come hang out with me on Facebook or Instagram. Follow me @chartingcoach to get more practical tools to help you create sustainable clinical medicine in your life. **** Questions? Comments? Want to share how this podcast has helped you? Shoot me an email at admin@reachcareercoaching.ca. I would love to hear from you.

Today's podcast is titled “Culture in America: The Three Biggest Challenges Facing Western Civilization, Part One.” Recorded in 2007, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas and former CIA official, author, and recipient of the U.S. National Intelligence Distinguished Service Medal, Herb Meyer discuss the three biggest challenges facing Western civilization. Listen now, and don't forget to subscribe to get updates each week for the Free To Choose Media Podcast.

Recorded on-site at AAPD 2025 in Denver, host Dr. Joel Berg is joined by dental entrepreneur Dr. Chris Lugo for a chat on the business side of dental office management. Dr. Lugo discusses his experiences as a multi-practice owner who also mentors residents and associates in the financial background important in business. This is a must-listen if you're considering owning your own practice. Guest Bio: Dr. Christopher Lugo brings over 20 years of experience as a pediatric dentist, healthcare leader, and strategic business consultant. As CEO of Dynamic Dental Management and owner of Puget Sound Pediatric Dentistry, Dr. Lugo has built a highly successful network of pediatric dental practices across the Pacific Northwest. Known for his expertise in practice operations, revenue growth, and team development, he has become a sought-after consultant for practices looking to scale efficiently while delivering outstanding patient care. A graduate of the Harvard School of Dental Medicine, Dr. Lugo also holds an MBA from the Kellogg School of Management, combining clinical knowledge with business acumen to navigate the complexities of modern dental practice management. His unique perspective has made him a respected voice in the industry, including his role as an expert defense witness and his current position as a Clinical Professor at UT Houston. Dr. Lugo's work exemplifies a commitment to advancing pediatric dentistry and supporting the next generation of dental professionals. Whether in the classroom, chairside, or boardroom, he remains dedicated to elevating standards in patient care and practice management. Currently based in Houston, Texas, he continues influencing the field through his leadership, innovation, and commitment to excellence. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Cracker Barrel is facing an uproar after changing their iconic logo. Why do companies change their brands sometimes when consumers seem to love them the way they are? Tim Calkins, Clinical Professor of Marketing at Northwestern University's Kellogg School of Management, joins us.

The Food and Drug Administration or FDA regulates roughly 78% of the US food supply. This includes packaged products, food additives, infant formula, ultra-processed foods, and lots more. However, an analysis by the Environmental Working Group found that 99% of new food ingredients enter our food supply through a legal loophole that skirts FDA oversight and seems, to me at least, to be incredibly risky. Today we're speaking with two authors of a recent legal and policy analysis published in the Journal Health Affairs. They explain what this loophole is and its risks and suggest a new user fee program to both strengthen the FDA's ability to regulate food ingredients and address growing concerns about food safety. Our guests are Jennifer Pomeranz Associate Professor of Public Health Policy and Management at New York University School of Global Public Health and Emily Broad, director of Harvard Law School Center for Health Law and Policy Innovation. Interview Summary So Jennifer, let's start with you, help our listeners understand the current situation with food ingredient oversight. And what is this legal loophole that allows food companies to add new ingredients without safety reviews. Sure. So, Congress passed the Food Additives Amendment in 1958, and the idea was to divide food additives and generally recognized as safe ingredients into two different categories. That's where the GRAS term comes from generally recognized as safe? ‘Generally Recognized As Safe' is GRAS. But it circularly defines food additives as something that's not GRAS. So, there's not actually a definition of these two different types of substances. But the idea was that the food industry would be required to submit a pre-market, that means before it puts the ingredient into the marketplace, a pre-market petition to the FDA to review the safety. And then the FDA promulgates a regulation for safe use of a food additive. GRAS ingredients on the other hand, initially thought of as salt, pepper, vinegar, are things like that would just be allowed to enter the food supply without that pre-market petition. The problem is the food industry is the entity that decides which category to place each ingredient. There's no FDA guidance on which category they're supposed to ascribe to these ingredients. What has happened is that the food industry has now entered into the food supply an enormous amount of ingredients under what we call the GRAS loophole, which is allowing it to just bring it to the market without any FDA oversight or even knowledge of the ingredient. So, in essence, what we're having now is that the food industry polices itself on whether to submit this pre-market petition for a food additive or just include it in its products without any FDA knowledge. When you said ‘enormous number of such things,' are we talking dozens, hundreds, thousands? Nobody knows, but the environmental working group did find that 99% of new ingredients are added through this loophole. And that's the concerning part. Well, you can look at some ultra-processed foods and they can have 30 or 40 ingredients on them. That's just one food. You can imagine that at across the food supply, how many things there are. And there are these chemicals that nobody can pronounce. You don't know what's going on, what they are, what they're all about. So, what you're saying is that the food industry decides to put these things in foods. There's some processing reason for putting them in. It's important that the public be protected against harmful ingredients. But the food industry decides what's okay to put in and what's not. Are they required to do any testing? Are there criteria for that kind of testing? Is there any sense that letting the industry police itself amounts to anything that protects the public good? Well, the criteria are supposed to be the same for GRAS or food additives. They're supposed to be meeting certain scientific criteria. But the problem with this is that for GRAS ingredients, they don't have to use published data and they can hold that scientific data to themselves. And you mentioned food labels, the ingredient list, right? That doesn't necessarily capture these ingredients. They use generic terms, corn oil, color additive, food additive whatever. And so, the actual ingredient itself is not necessarily listed on the ingredient list. There is no way to identify them and it's unknown whether they're actually doing the studies. They can engage in these, what are called GRAS panels, which are supposed to be experts that evaluate the science. But the problem is other studies have found that 100% of the people on these GRAS panels have financial conflicts of interest. Okay, so let me see if I have this right. I'm a food company. I develop a new additive to provide color or flavor or fragrance, or it's an emulsifier or something like that. I develop a chemical concoction that hasn't really been tested for human safety. I declare it safe. And the criteria I use for declaring it set safe is putting together a panel of people that I pay, who then in a hundred percent of cases say things are. That's how it works? I can't say that in a hundred percent of cases they say it's safe, but a hundred percent of the people have financial conflicts of interest. That's one of the major concerns there. Well, one can't imagine they would continue to be paid... Exactly. This sounds like a pretty shaky system to be sure. Emily: I wanted to add a couple other really quick things on the last discussion. You were saying, Kelly, like they're using a panel of experts, which indeed are paid by them. That would be best case in some cases. They're just having their own staff say, we think this is generally recognized as safe. And I think there's some examples we can give where there isn't even evidence that they went to even any outside people, even within industry. I think that the takeaway from all of that is that there's really the ability for companies to call all the shots. Make all the rules. Not tell FDA what they're doing. And then as we talked about, not even have anything on the label because it's not a required ingredient if it's, used as part of a processing agent that's not a substance on there. So I was feeling pretty bad when Jennifer is talking about these panels and the heavy conflict... Even worse. Of interest, now I feel worse because that's the best case. Totally. And one other thing too is just you kind of warmed this up by talking about this loophole. When we put an earlier article out that we wrote that was about just this generally recognized as safe, the feedback we got from FDA was this isn't a loophole. Why are you calling this a loophole? And it's pretty clear that it's a loophole, you know? It's big enough to drive thousands of ingredients through. Yes, totally. Emily, you've written about things like partially hydrogenated vegetable oils, trans fats, and red dye number three in particular. Both of which FDA has now prohibited in food. Can you walk us through those cases? You asked about partially hydrogenated oils or trans-fat, and then red dye three, which are two examples that we talk about a little bit in our piece. Actually, one of those, the partially hydrogenated oils was allowed in food through the generally recognized as safe definition. And the other was not. But they are both really good examples of another real issue that FDA has, which is that not only are they not doing a good job of policing substances going into food on the front end, but they do an even worse job of getting things out of food on the backend, post-market once they know that those substances are really raising red flags. And you raised two of the prime examples we've been talking about. With partially hydrogenated oils these are now banned in foods, but it took an extremely long time. Like the first evidence of harm was in the mid-nineties. By 2005, the Institute of Medicine, which is now the National Academies, said that intake of trans fat, of partially hydrogenated oils, should be as low as possible. And there was data from right around that time that found that 72,000 to 228,000 heart attacks in the US each year were caused by these partially hydrogenated oils. And on FDA's end, they started in early 2000s to require labeling. But it wasn't until 2015 that they passed a final rule saying that these substances were not generally recognized as safe. And then they kept delaying implementation until 2023. It was basically more than 20 years from when there was really clear evidence of harm including from respected national agencies to when FDA actually fully removed them from food. And red dye number three is another good example where there were studies from the 1980s that raised concerns about this red dye. And it was banned from cosmetics in 1990. But they still allowed it to be added to food. And didn't ban it from food until early this year. So early 2025. In large part because one of the other things happening is states are now taking action on some of these substances where they feel like we really need to protect consumers in our states. And FDA has been doing a really poor job. California banned red dye about 18 months before that and really spurred FDA to action. So that 20-year delay with between 72,000 and 228,000 heart attack deaths attributable to the trans fats is the cost of delay and inaction and I don't know, conflicts of interest, and all kinds of other stuff that happened in FDA. So we're not talking about something trivial by any means. These are life and death things are occurring. Yes. Give us another example, if you would, about something that entered the food supply and caused harm but made it through that GRAS loophole. The example that I've talked about both in some of the work we've done together and also in a perspective piece in the New England Journal of Medicine that really focused on why this is an issue. There was this substance added to food called tara flour. It came on the scene in 2022. It was in food prepared by Daily Harvest as like a protein alternative. And they were using it from a manufacturer in South America who said we have deemed this generally recognized as safe. Everything about that is completely legal. They deemed it generally recognized as safe. A company put it into food, and they sold that. Up until that point, that's all legal. What happened was very quickly people started getting really sick from this. And so there were, I think, about 400 people across 39 states got sick. Nearly 200 people ended up in the hospital, some of them with liver failure because of this toxicity of tara flour. And so FDA followed the thread they did help work with the company to do a voluntary recall, but it then took them two years, until May, 2024, to declare tara flour not generally recognized as safe. So I think, in some ways, this is a great example because it shows how it's so immediate, the impact of this substance that, again, was legally added to food with no oversight. In some ways it's a misleading example because I think so many of the substances in food, it's not going to be so clear and so immediate. It's going to be year over year, decade over decade as part of a full diet that these are causing cardiovascular risk, thyroid disease, cancer risk, those kinds of things. I'd love to hear from either of you about this. Why is FDA falling down on the job so badly? Is it that they don't have the money to do the necessary testing? Do they not have the authority? Is there not the political will to do this? Is there complete caving into the food industry? Just let them do what they want and we're going let it go? Jennifer: All of the above? Everything you just said? It's all of the above. Emily: Jen, do you wanna talk about the money side? Because that sort of gets to the genesis of the article we worked on, which was like maybe there's a creative solution to that piece. Yes, I'd love to hear about that because I thought that was a very creative thing that you guys wrote about in your paper. That there would be an industry user fee to help produce this oversight. Tell us what you had in mind with that. And then then convince me that FDA would appropriately use this oversight and do its job. So, the idea in the paper was proposing a comprehensive user fee program for the food branch of the FDA. The FDA currently collects user fees for all of human drugs, animal drugs, medical devices, etc. With Tobacco, it's a hundred percent funded by user fees. But food, it only gets 1% of its funding through user fees. And it's important to note user fees fund processes. They don't fund outcomes. It's not like a bribe. And the idea behind user fees and why industry sometimes supports them is actually to bring predictability to the regulatory state. It brings efficiency to reviews. And then this all allows the industry to anticipate timelines so they can bring products to market and know when they're going be able to do it. In the food context, for example, the FDA is required to respond to those food additives petitions that we talked about within 180 days. But they can't respond in time. And they have a lot of timelines that are required of them in the food context that they can't meet. They can't meet their timelines because they're so underfunded. So, we proposed a comprehensive user fee. But one of the main reasons that we think a user fee is important is to address the pre-market issues that I talked about and the post-market issues that Emily talked about. In order to close that GRAS loophole, first of all, FDA needs to either reevaluate its authorities or Congress needs to change its authorities. But it would need resources to be able to do something pre-market. Some of the ideas we had was that the user fee would fund some type of either pre-market review, pre-market notification, or even just a pre-market system where the FDA determines whether a proposed ingredient should go through the GRAS avenue, or through food additive petition. So at least that there will be some type of pre-market oversight over all the ingredients in the food supply. And then also the FDA is so severely lacking in any type of comprehensive post-market into play, they would have the resources to engage in a more comprehensive post-market review for all the ingredients. Could you see a time, and I bring this up because of lawsuits against the food industry for some of these additives that are going on now. The state attorney's generals are starting to get involved, and as you said, Emily, the some states are taking legislative action to ban certain things in the food supply. Do you think there could come a time when the industry will come to government pleading to have a user fee like this? To provide some standardization across jurisdictions, let's say? So, there's two things. The first is Congress has to pass the user fee, and historically, actually, industry has done exactly what you said. They have gone to Congress and said, you know what? We want user fees because we want a streamlined system, and we want to be able to know when we're bringing products to market. The problem in the context of food for the issues we're talking about is that right now they can use the GRAS loophole. So, they have very little incentive to ask for user fees if they can bring all their ingredients into the market through the GRAS loophole. There are other areas where a user fee is very relevant, such as the infant formula 90 day pre-market notification, or for different claims like health claims. They might want user fees to speed those things up, but in terms of the ingredients, unless we close the GRAS loophole, they'd have little incentive to actually come to the table. But wouldn't legal liability change that? Let's say that some of these lawsuits are successful and they start having to pay large settlements or have the State Attorneys General, for example, come down on them for these kinds of things. If they're legally liable for harm, they're causing, they need cover. And wouldn't this be worth the user fee to provide them cover for what they put in the food supply? Yes, it's great to have the flexibility to have all these things get through the loophole, but it'd be great as well to have some cover so you wouldn't have so much legal exposure. But you guys are the lawyers, so I'm not sure it makes sense. I think you're right that there are forces combining out in the world that are pushing for change here. And I think it's hard to disentangle how much is it that industry's pushing for user fees versus right now I think more willing to consider federal regulatory changes by either FDA or by Congress. At the state level this is huge. There's now becoming a patchwork across states, and I think that is really difficult for industry. We were tracking this year 93 bills in 35 states that either banned an additive in the general public, banned it in schools. Banned ultra-processed foods, which most of the states, interestingly, have all defined differently. But where they have had a definition, it's been tied to various different combinations of additives. So that's going on. And then I think you're right, that the legal cases moving along will push industry to really want clear and better standards. I think there's a good question right now around like how successful will some of these efforts be? But  what we are seeing is real movement, both in FDA and in Congress, in taking action on this. So interestingly, the Health Affairs piece that we worked on was out this spring. But we had this other piece that came out last fall and felt like we were screaming into the void about this is a problem generally recognized as safe as a really big issue. And suddenly that has really changed. And so, you know, in March FDA said they were directed by RFK (Robert F. Kennedy), by HHS (Health and Human Services) to really look into changing their rule on generally recognized as safe. So, I know that's underway. And then in Congress, multiple bills have been introduced. And I know there are several in the works that would address additives and specifically, generally recognized as safe. There's this one piece going on, which is there's forces coalescing around some better method of regulation. I think the question's really going to also be like, will Congress give adequate resources? Because there is also another scenario that I'm worried about that even if FDA said we're going now require at least notification for every substance that's generally recognized as safe. It's a flood of substances. And they just, without more resources, without more staff devoted to this, there's no way that they're going to be able to wade through that. So, I think that either the resources need to come from user fees, or at least partially from user fees, from more appropriations and I think, In my opinion, they are able to do that on their own. Even given where current administrative law stands. Because I think it's very clear that the gist of the statute is that FDA should be overseeing additives. And I think a court would say this is allowing everything to instead go through this alternative pathway. But I really think FDA's going to need resources to manage this. And perhaps more of a push from Congress to make sure that they really do it to the best of their ability. I was going to say there's also an alternative world where we don't end up spending any of these resources, and they require the industry just to disclose all the ingredients they've added to food and put it on a database. This is like low hanging fruit, not very expensive, doesn't require funding. And then the NGOs, I hope, would go to work and say, look at this. There is no safety data for these ingredients. You know, because right now we just can't rely on FDA to do anything unless they get more funding to do something. So, if FDA doesn't get funding, then maybe this database where houses every ingredient that's in the food supply as a requirement could be a low resource solution. Jennifer, I'll come back to you in a minute because I'd like to ask how worried should we be about all this stuff that's going into food. But Emily, let me ask you first, does FDA have the authority to do what it needs to do? Let's say all of a sudden that your wish was granted and there were user fees would it then be able to do what needs to be done? I think certainly to be able to charge these user fees in almost all areas, it right now doesn't have that authority, and Congress would need to act. There's one small area which is within the Food Safety Modernization Act for certain types of like repeat inspections or recalls or there's a couple other. FDA isn't charging fees right now because they haven't taken this one step that they need to take. But they do have the authority if they just take those steps. But for everything else, Congress has to act. I think the real question to me is because we now know so many of these substances are going through this GRAS pathway, the question is really can they do everything they need to do on their own to close that loophole? And again, my opinion is Congress could make it clear and if Congress were to act, it would be better. Like they could redefine it in a way that was much more clear that we are drawing a real line. And most things actually should be on the additive side of the line rather than the generally recognized as safe side of the line. But even with their current authority, with the current definition, I think FDA could at least require notification because they're still drawing a line between what's required for additives, which is a very lengthy pre-market process with, you know, a notice and comment procedure and all of these things. My take is FDA do what you can do now. Let's get the show on the road. Let's take steps here to close up the loophole. And then Congress takes time. But they definitely can even strengthen this and give a little more, I think, directives to FDA as to how to make sure that this loophole doesn't recur down the line. In talks that I've given recently, I've shown an ingredient list from a food that people will recognize. And I ask people to try to guess what that food is from its ingredient list. This particular food has 35 ingredients. You know, a bunch of them that are very hard to pronounce. Very few people would even have any idea at all what those ingredients do. There's no sense at all about how ingredient number 17 would interact with ingredient 31, etc. And it just seems like it's complete chaos. And I don't want to take you guys outside your comfort zone because your backgrounds are law. But Jennifer, let me ask you this. You have a background in public health as well. There are all kinds of reasons to be worried about this, aren't there? There are the concerns about the safety of these things, but then there's a concern about what these ultra-processed ingredients do to your metabolism, your ability to control your weight, to regulate your hunger and things like that. It sounds this is a really important thing. And it's affecting almost everybody in the country. The percentage of calories that are now coming from ultra-processed foods is over 50% in both children and adults. So it sounds like there's really reason to worry. Would you agree? Yes. And also, the FDA is supposed to be overseeing the cumulative effects of the ingredients and it doesn't actually enforce that regulation. Its own regulation that it's supposed to evaluate the cumulative effects. It doesn't actually enforce this. So by cumulative effects do you mean the chronic effects of long term use? And, having these ingredients across multiple products within one person's consumption. Also, the FDA doesn't look at things like the effect on the gut microbiome, neurotoxicity, even cancer risk, even though they're supposed to, they say that if something is GRAS, they don't need to look at it because cancer risk is relegated only to food additives. So here we're at a real issue, right? Because if everything's entering through the GRAS loophole, then they're not looking at carcinogen effects. So, I think there is a big risk and as Emily had said earlier, that these are sometimes long-term risks versus that acute example of tara flour that we don't know. And we do know from the science, both older and emerging science, that ultra-processed food has definite impact on not only consumption, increased consumption, but also on diet related diseases and other health effects. And by definition what we're talking about here are ultra-processed foods. These ingredients are only found in ultra-processed foods. So, we do know that there is cause for concern. It's interesting that you mentioned the microbiome because we've recorded a cluster of podcasts on the microbiome and another cluster of podcasts on artificial sweeteners. Those two universes overlap a good bit because the impact of the artificial sweeteners on some of them, at least on the microbiome, is really pretty negative. And that's just one thing that goes into these foods. It really is pretty important. By the way, that food with 35 ingredients that I mentioned is a strawberry poptart. Jennifer: I know that answer! Emily: How do you know that? Jennifer: Because I've seen Kelly give a million talks. Yes, she has. Emily: I was wondering, I was like, are we never going to find out? So the suspense is lifted. Let me end with this. This has been highly instructive, and I really appreciate you both weighing in on this. So let me ask each of you, is there reason to be optimistic that things could improve. Emily, I'll start with you. So, I've been giving this talk the past few months that's called basically like Chronic Disease, Food Additives and MAHA, like What Could Go Right and What Could Go Wrong. And so, I'm going give you a very lawyerly answer, which is, I feel optimistic because there's attention on the issue. I think states are taking action and there's more attention to this across the political spectrum, which both means things are happening and means that the narrative changing, like people are getting more aware and calling for change in a way that we weren't seeing. On the flip side, I think there's a lot that could go wrong. You know, I think some of the state bills are great and some of them are maybe not so great. And then I think this administration, you have an HHS and FDA saying, they're going to take action on this in the midst of an administration that's otherwise very deregulatory. In particular, they're not supposed to put out new regulations if they can get rid of 10 existing ones. There are some things you can do through guidance and signaling, but I don't think you can really fix these issues without like real durable legislative change. So, I'm sorry to be one of the lawyers here. I think the signals are going in the right direction, but jury is out a little bit on how well we'll actually do. And I hope we can do well given the momentum. What do you think, Jennifer? I agree that the national attention is very promising to these issues. The states are passing laws that are shocking to me. That Texas passing a warning label law, I would never have thought in the history of the world, that Texas would be the one to pass a warning label law. They're doing great things and I actually have hope that something can come of this. But I am concerned at the federal level of the focus on deregulation may make it impossible. User fees is an example of where they won't have to regulate, but they could provide funding to the FDA to actually act in areas that it has the authority to act. That is one solution that could actually work under this administration if they were amenable to it. But I also think in some ways the states could save us. I worry, you know, Emily brought up the patchwork, which is the key term the industry uses to try to get preemption. I do worry about federal preemption of state actions. But the states right now are the ones saving us. California is the first to save the whole nation. The food industry isn't going to create new food supply for California and then the rest of the country. And then it's the same with other states. So, the states might be the ones that actually can make some real meaningful changes and get some of the most unsafe ingredients out of the food supply, which some of the states have now successfully done. Bios Emily Broad Leib is a Clinical Professor of Law, Director of Harvard Law School Center for Health Law and Policy Innovation, and Founding Director of the Harvard Law School Food Law and Policy Clinic, the nation's first law school clinic devoted to providing legal and policy solutions to the health, economic, and environmental challenges facing our food system. Working directly with clients and communities, Broad Leib champions community-led food system change, reduction in food waste, food access and food is medicine interventions, and equity and sustainability in food production. Her scholarly work has been published in the California Law Review, Wisconsin Law Review, Harvard Law & Policy Review, Food & Drug Law Journal, and Journal of Food Law & Policy, among others. Professor Jennifer Pomeranz is a public health lawyer who researches policy and legal options to address the food environment, obesity, products that cause public harm, and social injustice that lead to health disparities. Prior to joining the NYU faculty, Professor Pomeranz was an Assistant Professor at the School of Public Health at Temple University and in the Center for Obesity Research and Education at Temple. She was previously the Director of Legal Initiatives at the Rudd Center for Food Policy and Obesity at Yale University. She has also authored numerous peer-reviewed and law review journal articles and a book, Food Law for Public Health, published by Oxford University Press in 2016. Professor Pomeranz leads the Public Health Policy Research Lab and regularly teaches Public Health Law and Food Policy for Public Health.

On this episode of Deans Counsel, Jim Ellis and Dave Ikenberry speak with Bernard "Bernie" Banks, Director of Rice University's Doerr Institute for New Leaders (and a Clinical Professor of Management within the University's Jesse H. Jones Graduate School of Business). The mission of the Doerr Institute “…is to elevate the leadership capacity of Rice students and to improve the practice of leader development in higher education.”  Most recently, Bernie served on the faculty and senior leadership team at Northwestern University's Kellogg School of Management from 2016-2024 prior to arriving at Rice.Bernie retired from the U.S. Army in 2016 as a Brigadier General after having successfully led West Point's Department of Behavioral Sciences & Leadership in his final assignment. In addition to having studied leadership extensively, he has led multiple military units ranging in size from 10 to over 3000 people.  In this instructive conversation, Bernie relates to our hosts some of the experiences he's gleaned through his decades as an inspiring leader, touching on topics such as:- his objectives as Director of the Doerr Institute- how he measures effectiveness- acquainting students with the leadership mindset- creative approaches to leadership developmentLearn more about Bernie BanksComments/criticism/suggestions/feedback? We'd love to hear it. Drop us a note.Thanks for listening.-Produced by Joel Davis at Analog Digital Arts--DEANS COUNSEL: A podcast for deans and academic leadership.James Ellis | Moderator | Dean of the Marshall School of Business at the University of Southern California (2007-2019)David Ikenberry | Moderator | Dean of the Leeds School of Business at the University of Colorado-Boulder (2011-2016)Ken Kring | Moderator | Co-Managing Director, Global Education Practice and Senior Client Partner at Korn FerryDeansCounsel.com

Help us expand our Muslim media project here: https://www.thinkingmuslim.com/membershipHow can we manage life's hardships and pain, and does our modern way of living explain why so many people find themselves in therapy today? Dr Rania Awaad is the Co-Founder and President of Maristan and a Clinical Professor of Psychiatry at Stanford University. She draws on both Islamic tradition and medical science to revive a legacy of holistic healing in which the psyche is understood through the ruh, qalb and nafs, offering a spiritually grounded alternative to Western approaches that often pathologise struggle while overlooking faith and growth.You can find Dr Rania Awaad here:X: https://x.com/drraniaawaadIG: https://www.instagram.com/dr.raniaawaadMaristan Project: https://maristan.org/Become a member here:https://www.thinkingmuslim.com/membershipOr give your one-off donation here:https://www.thinkingmuslim.com/donateListen to the audio version of the podcast:Spotify: https://open.spotify.com/show/7vXiAjVFnhNI3T9Gkw636aApple Podcasts: https://podcasts.apple.com/gb/podcast/the-thinking-muslim/id1471798762Purchase our Thinking Muslim mug: https://www.thinkingmuslim.com/merchFind us on:X: https://x.com/thinking_muslimLinkedIn: https://www.linkedin.com/company/the-thinking-muslim/Facebook: https://www.facebook.com/The-Thinking-Muslim-Podcast-105790781361490Instagram: https://www.instagram.com/thinkingmuslimpodcast/Telegram: https://t.me/thinkingmuslimBlueSky: https://bsky.app/profile/thinkingmuslim.bsky.socialThreads: https://www.threads.com/@thinkingmuslimpodcastFind Muhammad Jalal here:X: https://twitter.com/jalalaynInstagram: https://www.instagram.com/jalalayns/Sign up to Muhammad Jalal's newsletter: https://jalalayn.substack.comWebsite Archive: https://www.thinkingmuslim.comDisclaimer:The views expressed in this video are those of the individual speaker(s) and do not represent the views of the host, producers, platform, or any affiliated organisation. This content is provided for lawful, informational, and analytical purposes only, and should not be taken as professional advice. Viewer discretion is advised. Hosted on Acast. See acast.com/privacy for more information.

This episode is brought to you by Alma. Visit HelloAlma.com/ATPP to learn more Get the Couples Therapy 101 course: https://www.couplestherapistcouch.com/ Join the Couples Therapist Inner Circle: https://www.couplestherapistcouch.com/inner-circle-new Join The Couples Therapist Couch Facebook Group: https://www.facebook.com/groups/295562197518469/ In this episode, Shane talks with Dr. Dan Siegel about brain science & attachment. Dan is the Clinical Professor of Psychiatry at the UCLA School of Medicine, Executive Director of the Mindsight Institute, and Author of numerous books & articles on mindfulness & neurobiology. Hear how interpersonal neurobiology applies to couples therapy, why our brain plays such a big part in our relationships, how much attachment influences the present, the benefits of mindfulness, and how to work on the emotional health of your clients. To learn more about Dr. Dan Siegel, his courses, and his books, visit: DrDanSiegel.com MindsightInstitute.com  

Today's podcast is titled “Eminent Domain.” Recorded in 2003, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas speaks with professors Richard Epstein (University of Chicago), Gideon Kanner (Loyola Law School), Julie Forester (Southern Methodist University), and attorney Kenneth Wright about eminent domain.  Listen now, and don't forget to subscribe to get updates each week for the Free To Choose Media Podcast.

Kevin McTigue, Clinical Professor at the Kellogg School of Management at Northwestern University, joins Lisa Dent to discuss the Illinois Tollway’s plans to explore dynamic pricing. McTigue shares insight into how this flexible pricing model is already reshaping other industries, from traffic congestion fees to real-time grocery store pricing, and what it could mean for […]

Today's podcast is titled “An Intimate Conversation with Jim Lehrer, Part Two.” Recorded in 2007, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas, continues his interview with Jim Lehrer, anchor and executive editor of PBS’s The NewsHour with Jim Lehrer.  Listen now, and don't forget to subscribe to get updates each week for the Free To Choose Media Podcast.

0:00 - Cincy beatings 7:40 - Mamdani on defunding police 27:12 - Pelosi insider trading 47:44 - Host of “The Futures Edge Podcast” and special contributor to Wirepoints, Jim Iuorio, responds to Brandon Johnson's floated corporate head tax - "they're putting people against the wall who have options" For podcast updates & more @jimiuorio 01:06:34 - Clinical Professor of Law and Director of the Securities Law Clinic at Cornell Law School, William Jacobson: "You only have freedom on campuses if you are liberal, very liberal, far-left anarchist, or anti-Israel anti-American" Professor Jacobson is also the founder of LegalInsurrection.com and president of the Legal Insurrection Foundation 01:28:06 - SPORTS & POLITICS 01:47:53 - Chris Ferguson, professor of psychology at Stetson University: Dopamine Is Not Why Kids Love TikTok. Follow Chris on X @CJFerguson1111 02:09:49 - Martin Gurri, former CIA analyst, presently a Visiting Fellow at the Mercatus Center of George Mason University: Obama’s bruised ego was behind the corrupt plot to bring down Trump. Martin is also author of The Revolt of the Public and the Crisis of Authority in the New MillenniumSee omnystudio.com/listener for privacy information.

In this conversation, we delve into the science of food sensitivity testing, immune reactivity, and microbiome health with Dr. Aristo Vojdani. Dr. Vojdani is the Chief Scientific Advisor for Cyrex Labs in Arizona, a Clinical Professor in the Department of Preventive Medicine at Loma Linda University, and an Adjunct Professor of functional neurology at NUHS Lincoln College.  Join in to discover: The two immunology workshops that changed Dr. Vojdani's life. How to accurately measure antibodies using advanced scientific methods. The role that early detection plays in mitigating chronic disease.  What “natural killer” cells are, and how scientists are able to identify them. The science of digestive enzymes.  Dr. Vojdani holds a Ph.D. in microbiology and clinical immunology, with advanced postdoctoral training in tumor immunology at UCLA. Over the course of a distinguished 40-year career, his research has explored how environmental triggers contribute to the development of chronic and autoimmune diseases.  A pioneer in diagnostic innovation, Dr. Vojdani holds 15 U.S. patents for laboratory testing methods and has authored more than 120 peer-reviewed scientific publications. He currently serves as CEO and technical director of Immunosciences Lab, Inc. in Los Angeles, and contributes his expertise as an editorial board member for four scientific journals and guest editor for six others. Want to learn more about Dr. Vojdani and his intriguing work? Click here now! Episode also available on Apple Podcasts: http://apple.co/30PvU9C Keep up with Aristo Vojdani socials here: Instagram: https://www.instagram.com/immunsci/   X: https://x.com/draristovojdani 

On this week's episode, we hear Mishelle's phone call with Dr. Jayne Ness, Collin's treating physician, who shares concerning insights into Collin's treatment—notably, that she was never certain Collin had NMO and that she had serious concerns for abuse. Andrea then speaks with Dr. Kenneth Feldman, a Child Abuse Pediatrician and Clinical Professor of Pediatrics at the University of Washington, about how physicians become entangled with Munchausen by Proxy perpetrators. Dr. Feldman also discusses the online behavior of perpetrators. Andrea then traces Lisa's advocacy efforts following Collin's death, starting with a now-defunct 501(c)(3) organization and eventually leading to her work with the Guthy Jackson Foundation. Mishelle goes on to describe how, after Collin's passing, Lisa began faking her own illness.  *** Justice for Collin: Contact Birmingham PD https://docs.google.com/document/d/1tEg2mpbrwNJnuVMNdbHANCofEFYvH9_bO5MULHUxqLs/edit Andrea's August 1st event with Gregg Olsen: https://www.libertybaybooks.com/event/west-sound-crime-con-2025-local-authors-gregg-olsen-and-andrea-dunlop Order Andrea's new book The Mother Next Door: Medicine, Deception, and Munchausen by Proxy.  Click here to view our sponsors. Remember that using our codes helps advertisers know you're listening and helps us keep making the show!   Subscribe on YouTube where we have full episodes and lots of bonus content.  Follow Andrea on Instagram: @andreadunlop Buy Andrea's books here.  For more information and resources on Munchausen by Proxy, please visit MunchausenSupport.com The American Professional Society on the Abuse of Children's MBP Practice Guidelines can be downloaded here.  *** This season covers sensitive subject matter involving allegations of child abuse, medical child abuse (also known as Munchausen by proxy), and the death of a minor. All information presented is based on court records, first-person interviews, contemporaneous documentation, and publicly available sources. The podcast includes personal statements and perspectives from individuals directly involved in or affected by these events. These accounts represent their experiences and interpretations, and some statements reflect opinions that may be emotionally charged. Where appropriate, the reporting team has verified claims through official records or corroborating sources. Nothing in this podcast should be interpreted as a legal conclusion or diagnosis. All subjects are presumed innocent unless convicted in a court of law. This podcast is intended for informational and public interest purposes. This podcast contains audio excerpts from two phone conversations recorded in the states of Georgia and Alabama, respectively. Both recordings were obtained by a third-party source, who acted in accordance with the relevant one-party consent laws of those states, which allow for the lawful recording of a conversation with the consent of one participant. These recordings were subsequently shared with the producers of this podcast after the fact, and were not made by or at the direction of the podcast team or its parent organization. The podcast producers have made good-faith efforts to confirm the legal compliance of the original recordings, and are presenting these materials in the context of public interest reporting. The inclusion of this audio is intended for journalistic, educational, and documentary purposes in alignment with the principles of fair use and First Amendment protections. Listeners are advised that the views expressed in the recordings are those of the individuals speaking and do not necessarily reflect the views of the producers or affiliated entities. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Harry Kraemer is an executive partner with Madison Dearborn Partners, a private equity firm based in Chicago, and a Clinical Professor of Leadership at Northwestern University's Kellogg School of Management. He previously served as chairman and CEO of Baxter International, a $12 billion global healthcare company. He is also the author of three bestselling leadership books and a sought-after speaker.  Harry joined host Robert Glazer on ⁠the Elevate Podcast⁠ to discuss his leadership career, why self-awareness is essential to leadership, tips for success as a CEO, and more. This episode of the Elevate Podcast is sponsored by: Shopify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠shopify.com/elevate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Indeed: ⁠⁠⁠⁠⁠⁠indeed.com/elevate⁠⁠⁠⁠⁠⁠ Framer: ⁠⁠⁠⁠⁠⁠framer.com⁠⁠⁠⁠⁠⁠ BambooHR: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠bamboohr.com/freedemo⁠⁠⁠⁠⁠⁠ IDEO U: ⁠⁠⁠⁠⁠⁠ideou.com/elevate⁠⁠ Castbox: ⁠castbox.fm Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Marc Siegel, clinical professor of medicine & a Fox News contributor, calls into the show to discuss President Trump's health, dispelling rumors about his leg condition, and contrasting it with the lack of transparency in the Biden administration. Additionally, Dr. Siegel touches on the success and controversies surrounding In-N-Out Burger, specifically its lack of veggie options. The conversation also explores the rising trend of non-obese individuals using GLP-1 medications for minor weight loss and the potential risks associated with such practices, emphasizing the importance of lifestyle changes and exercising. Learn more about your ad choices. Visit megaphone.fm/adchoices

Build a thriving, loyal community—without chasing members or cranking out content 24/7. Join us for free:

Today's podcast is titled “An Intimate Conversation with Jim Lehrer, Part One.” Recorded in 2002, Dennis McCuistion, former Clinical Professor of Corporate Governance and Executive Director of the Institute for Excellence in Corporate Governance at the University of Texas at Dallas interviews Jim Lehrer, anchor and executive editor of PBS’s The NewsHour with Jim Lehrer”. Listen now, and don't forget to subscribe to get updates each week for the Free To Choose Media Podcast.

We begin this week's episode with a young Mishelle struggling to adjust to life with her grandparents, finding it difficult to accept both the separation from her parents and the reality of what her mother had done. Meanwhile, Lisa is in the midst of a police investigation, undergoing a psychological evaluation and attending therapy. We hear from Bea Yorker—an expert in Munchausen by Proxy and the President of Munchausen Support—and Dr. Mary Sanders, a Clinical Professor of Psychiatry and Behavioral Sciences at Stanford University and a member of APSAC's Munchausen by Proxy committee. They explain what should have been considered during Lisa's evaluation and what it truly means to "treat" someone with Munchausen by Proxy. Armed with letters from therapists attesting to her remorse, Lisa turns to the online forum MAMA (Mothers Against Munchausen Allegations) to build her case for court. There, she begins digging for information on enemy number one: Bea Yorker.  *** Andrea's August 1st event with Gregg Olsen: https://www.libertybaybooks.com/event/west-sound-crime-con-2025-local-authors-gregg-olsen-and-andrea-dunlop Order Andrea's new book The Mother Next Door: Medicine, Deception, and Munchausen by Proxy.  Click here to view our sponsors. Remember that using our codes helps advertisers know you're listening and helps us keep making the show!   Subscribe on YouTube where we have full episodes and lots of bonus content.  Follow Andrea on Instagram: @andreadunlop Buy Andrea's books here.  For more information and resources on Munchausen by Proxy, please visit MunchausenSupport.com The American Professional Society on the Abuse of Children's MBP Practice Guidelines can be downloaded here.  *** This season covers sensitive subject matter involving allegations of child abuse, medical child abuse (also known as Munchausen by proxy), and the death of a minor. All information presented is based on court records, first-person interviews, contemporaneous documentation, and publicly available sources. The podcast includes personal statements and perspectives from individuals directly involved in or affected by these events. These accounts represent their experiences and interpretations, and some statements reflect opinions that may be emotionally charged. Where appropriate, the reporting team has verified claims through official records or corroborating sources. Nothing in this podcast should be interpreted as a legal conclusion or diagnosis. All subjects are presumed innocent unless convicted in a court of law. This podcast is intended for informational and public interest purposes. This podcast contains audio excerpts from two phone conversations recorded in the states of Georgia and Alabama, respectively. Both recordings were obtained by a third-party source, who acted in accordance with the relevant one-party consent laws of those states, which allow for the lawful recording of a conversation with the consent of one participant. These recordings were subsequently shared with the producers of this podcast after the fact, and were not made by or at the direction of the podcast team or its parent organization. The podcast producers have made good-faith efforts to confirm the legal compliance of the original recordings, and are presenting these materials in the context of public interest reporting. The inclusion of this audio is intended for journalistic, educational, and documentary purposes in alignment with the principles of fair use and First Amendment protections. Listeners are advised that the views expressed in the recordings are those of the individuals speaking and do not necessarily reflect the views of the producers or affiliated entities. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Our health and the health of our soil are deeply intertwined. Modern agriculture has become heavily dependent on synthetic inputs and industrial practices that strip the land of vitality, and the farmers of agency. Many farmers no longer eat what they grow, suffer from poor health, and experience alarming rates of depression and suicide. But there's a path forward: regenerative farming not only restores soil health and increases nutrient density in food, it also revitalizes rural communities and offers economic resilience. By reconnecting with natural systems and rebuilding diversity in our soil, food, and microbiomes, we reclaim both ecological balance and human well-being. In this episode, I discuss, along with Allen Williams, Dr. Daphne Miller, and Ian Somerhalder the many facets of modern-day farming, including what we need to pay attention to and why we need to reclaim our soil. Allen Williams is a founding partner of Understanding Ag, LLC and the Soil Health Academy, and is a partner in Joyce Farms, Inc. He has consulted with more than 4,000 farmers and ranchers in the US and other countries, on operations ranging from a few acres to over 1 million acres. Allen and his partners pioneered many of the early regenerative agriculture principles and practices and now teach those to farmers globally. He is a “recovering academic,” having served 15 years on the faculty at Louisiana Tech University and Mississippi State University teaching genetics and physiology. Allen has been featured in the Carbon Nation film series, Soil Carbon Cowboys, on the Dr. Oz show, ABC Food Forecast News, and in Kiss The Ground, A Regenerative Secret, The Farmer's Footprint film series, and the Sacred Cow film series.  Dr. Daphne Miller is a practicing family physician, Clinical Professor at the University of California San Francisco, and Founder of the Health from the Soil Up Initiative. She is the author of two books: The Jungle Effect: Healthiest Diets from Around the World and Farmacology: Total Health from the Soil Up. A pioneer in the “Healthy Parks, Healthy People” initiative, Miller helped build linkages between our medical system and our park system and writes her patients “park prescriptions” to get outdoors. She also developed a soil learning lab for health professionals at Paicines Ranch in Hollister California. Ian Somerhalder is an American actor, philanthropist, and entrepreneur. Best known for his iconic roles on "Lost" and "The Vampire Diaries," he is co-founder of The Absorption Company (a revolutionary supplement company formulated for increased absorption) and co-owner of Brother's Bond Bourbon. His recent work includes executive producing the documentary "Common Ground" (2023), which highlights regenerative agriculture's innovative solutions to combat climate change. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: Can Regenerative Agriculture Reverse Climate Change And Chronic Disease? Why Your Health Depends on the Soil Why Our Farms Hold the Key to a Healthier Future